Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women
- Registration Number
- NCT03212781
- Lead Sponsor
- Assiut University
- Brief Summary
Iron deficiency is the most prevalent nutritional deficiency and the most common cause of anemia .It is characterized by a defect in hemoglobin synthesis, resulting in red blood cells that are abnormally small (microcytic) and contain a decreased amount of hemoglobin (hypochromic).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 66
Inclusion Criteria
- Hemoglobin < 10 g/dL
- Gestational age between 14-28 weeks.
- Willingness to participate and signing the informed consent form.
Exclusion Criteria
- Iron overload or disturbances in utilization of iron
- Decompensated liver cirrhosis and active hepatitis
- Active acute or chronic infections
- History of multiple allergies
- Known hypersensitivity to parenteral iron or any recipients in the investigation drug products
- Erythropoietin treatment within 8 weeks prior to the screening visit
- Other iron treatment or blood transfusion within 4 weeks prior to the screening visit
- Planned elective surgery during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description oral iron Ferrous Fumarate patients will receive oral iron intravenous iron Iron dextran patients will receive intravenous iron as total dose infusion
- Primary Outcome Measures
Name Time Method The change in Hemoglobin concentration from baseline to 8 weeks therapy 8 weeks measure hemoglobin level before and after treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Assiut Faculty of Medicine
🇪🇬Assiut, Egypt